News & Insights

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic...

Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for...

Our viral drug product manufacturing facility in Rockville, MD is home to our INTEGRA® high-speed bulk filling line, with fully...

Located in Thörishaus, Switzerland, just outside of Bern, our European-based site has expertise in mammalian, microbial, and...

Emergent recently had the pleasure of participating in the Molecule to Market Podcast hosted by Ramen Sehgal from from ra...

As a CDMO, Emergent has been working for more than two decades to develop, manufacture and deliver protections against public...

Many CDMOs specialize in certain parts of the drug development lifecycle. Meanwhile, integrated turn-key offerings that support...

Emergent is pleased to announce the addition of two senior leaders to its  CDMO and Quality & Compliance organizations.

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently shared his insights with Pharma...

Innovation in cancer therapeutics is moving at an accelerated pace. Advancements in the development and manufacturing of...

From analytical development to drug substance and drug product process development and scale-up, we can help advance your...

As a drug delivery system, lipid-based formulations provide improved stability of an API and allow for safe, efficient delivery...

Our viral drug product manufacturing facility in Rockville, MD is home to our INTEGRA® high-speed bulk filling line, with fully...

Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents...

• Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...

Successful downstream processing provides isolation of the molecule of interest from extraneous constituents before formulation,...

Mitigating risk is a key consideration for biopharmaceutical companies when planning their clinical trial material and/or drug...

With the expansion of our viral drug product manufacturing facility in Rockville, Maryland well underway, we have begun...

There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug...

Our state-of-the-art Vanrx® SA25 Aseptic Filling Workcell can be deployed to support your clinical or commercial drug product...

“The Vanrx SA25 Aseptic Filling Workcell is a state-of-the-art machine, providing our clients with a high level of sterility...

Our drug product manufacturing facility in Rockville, Maryland is undergoing an expansion that will soon house a...

Watch our latest webinar on the topic of aseptic fill/finish and isolator-based technology for pre-sterilized syringes,...

In a recent Pharmaceutical Technology article, Emergent experts provide their insights on selection of technologies for vaccine...

Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing...

GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. ...

Excerpt taken from BioPharm International October 2020 Regulatory Sourcebook article titled: GMPs Guide COVID-19 Vaccine...

Jee Look, senior director of drug product development for Emergent BioSolutions recently contributed to an article in ...

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past...

Emergent BioSolutions, a Wells Fargo Corporate & Investment Banking customer since 2011, helps governments respond to health...

Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions recently contributed to an editorial...

“Emergent has a long, successful history of working with the US government to develop, manufacture, and deliver safe and...

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently contributed to an editorial in ...

In a recent article with BioProcess International, Syed T. Husain, senior vice president & CDMO business unit head at Emergent...

Read the latest news coverage of Emergent's insights and involvement in the fight against COVID-19. Last Updated: Thursday,...

Dino Muzzin, Senior Vice President, Manufacturing Operations at Emergent, recently contributed to an article in BioPharm...

Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical...

• Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...

Watch our latest webinar on the topic of how drug developers can maximize capacity, capabilities and expertise for pandemic...

GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)

Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby...

What are innovators doing to speed up the path to treating and preventing COVID-19?

The novel coronavirus has quickly taken...

• CDMO agreement for NanoFlu to support pathway to licensure
• Expanded collaboration now includes NanoFlu and COVID-19 vaccine...

Original news coverage of Novavax's agreement with Emergent BioSolutions to manufacture and develop an experimental oral vaccine...

Original news coverage of Vaxart's agreement with Emergent BioSolutions to manufacture and develop an experimental oral vaccine...

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...

GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...